Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This micronutrient combination, comprising thiamine (B1), riboflavin (B2), pyridoxine (B6), niacin (B3), cobalamin (B12), ascorbic acid (C), and tocopherol (E), was developed and evaluated by the National Institute of Allergy and Infectious Diseases (NIAID) as a supportive therapy for patients with pulmonary tuberculosis. In a landmark randomized, double-blind, placebo-controlled trial (NCT00197704) conducted in Tanzania, this regimen was administered to both HIV-infected and HIV-negative adults starting TB chemotherapy. The intervention aims to correct nutritional deficiencies, enhance immune competence, and mitigate oxidative stress. Clinical findings demonstrated that the supplementation significantly reduced the risk of TB recurrence and mortality, particularly in patients co-infected with HIV. The vitamins in this combination function as essential metabolic cofactors and systemic antioxidants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine + riboflavin + pyridoxine + niacin + cobalamin + ascorbic acid + tocopherol.